Why is Krystal Biotech stock sliding today?
Krystal Biotech (KRYS) shares fell about 6% in pre-open after it reported Q2 2026 results. The company posted $119.2M in global VYJUVEK net revenue, up 24% year over year but below analyst consensus near $126M. Gross margin was 95% and prescribers rose above 640, but the revenue miss drove selling.
How this was made
The 30-second read
Why it matters
KRYS is reacting to a top-line miss, with the article emphasizing that operational positives were overshadowed by revenue coming in below analyst expectations.
Market read
Traders can use the consensus revenue miss and the described gap-up reversal as a near-term signal for positioning and risk controls around KRYS.
What to watch
The article does not quantify guidance, cash burn, or pipeline updates; those could offset the revenue miss if they were strong but are not discussed here.
Background
The piece frames KRYS as having run up into earnings near its 52-week high, making consensus misses more likely to trigger a reversal.
Ticker impact
Krystal Biotech shares fell 6.2% pre-open after Q2 2026 revenue of $119.2M missed consensus near $126M.
Bearish near-term bias as traders reprice VYJUVEK commercial trajectory after the top-line shortfall.
The article cites a concrete earnings datapoint (revenue $119.2M vs ~$126M consensus) and links it to the sharp gap-up then reversal pattern.
Market effects
Limited evidence of sector contagion since no peers are cited as having negative news.
No specific regional spillover described; move is characterized as company-specific.
No global macro or cross-border catalyst tied to KRYS beyond general market tone.
Counterpoint
Operational metrics (95% gross margins, prescriber base expansion) may support a rebound if investors refocus on longer-term commercialization rather than the single-quarter miss.
Key entities
- companyKrystal Biotech
Subject of the article; stock slid after Q2 2026 results showed revenue below consensus.
- productVYJUVEK
The revenue line item discussed; $119.2M global net revenue in Q2 2026.
- analyst_firmJefferies
Maintained a Buy rating and a price target above current levels, but no new upgrade/PT increase was reported today.
